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Abstract 
 
Umbilical cord blood hematopoietic stem cell transplantation (UCB-HSCT) is an increasing 
area both clinical and translational investigation. The main hurdle of this approach is a 
delayed engraftment (or even a graft failure) that accounts the most of the transplant-
related mortality. To gain insight on the factors that may influence UCB engraftment is 
important to implement the clinical procedure. The interaction of hematopoietic 
progenitors with the stroma is the key process in this setting. Nevertheless, the 
establishment of a good in vitro model to evaluate three-dimensionally (3D) system part of 
the complex BM microenvironment are not well established.  
In this study we have tried to develop an artificial BM niche by using a scaffold of Conduit-
TCP (3D) together with human marrow mesenchymal stem cells (MSC). MSC were 
differentiated to stromal cells using the technology of classic long term bone marrow 
cultures (LTBMC). For this purpose, CD34+ cells from UCB were cultured for 5 weeks in 
this 3D-BM niche construct (3D system), demonstrating the capacity of this construct to 
support the maintenance of immature progenitors in culture, besides the differences in 
colony formation between this 3D system and the conventional two dimensional cultures 
(2D system) were not statistically significant.  
To complement the in vitro studies, we developed an in vivo experimental model to 
evaluate the engraftment capacity of this human-BM niche construct by implanting them 
subcutaneously in NOD/SCID mice after 4 weeks or 5 weeks of in vitro culture, showing 
better engraftment of the former group both at 3 and 6 weeks after transplantation of 
human UCB CD34+ cells. When compared this approach to a control group where the 3D-
BM niche was developed in vivo by implanting the scaffold with undifferentiated human 
MSC, the former group had higher engraftment of human hematopoietic cells (CD45+) at 3 
weeks postransplant on peripheral blood and 6 weeks on BM, with myeloid engraftment 
(CD13+). The control group presented higher human lymphoid cells (CD19+) when CD34+ 
cells were transplant intravenously and lower human CD19+ cells with a predominant 
human myeloid graft when the HSC were subcutaneously transplanted.  
The 6 weeks after transplantation an ex vivo study was performed. Immunohistochemistry 
and immunofluorescence assays demonstrated the homing and engraftment of the human 
cells into the 3D-BM niche in vitro constructs that were subcutaneously implanted. In 
addition, human MSC from the scaffolds contributed to form new cells in the 
microenvironment, contributing also to angiogenesis. By employing enhanced cyan 
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fluorescent protein-marked human MSC we were able to track them close to the 
endosteal zone.   
In summary, the 3D-BM niche constructs allowed the growth, differentiation and migration 
of HSC in a 3D humanized environment effectively mimicking the natural in vivo bone 
marrow environment that allows the maintenance and proliferation of hematopoietic cells 
both in vivo and in vitro. This model permits the study of normal and pathological 
hematopoiesis and its relationship with the stroma. 
 
Keywords: Hematopoietic stem cells – Three-dimensional system – Long term culture – 
Mesenchymal stem cells – Expansion - UCB CD34+ cells - NOD/SCID mouse  
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Resumo 
 
O transplante de células progenitoras/estaminais hematopoiéticas do sangue do cordão 
umbilical (SCU) é uma das terapias disponíveis para a clínica e uma área em expansão 
na investigação.  O obstáculo principal da utilização destes progenitores está associado a 
uma lenta recuperação dos doentes, levando a um aumento no risco de falência do 
enxerto, incrementando a incidência de mortalidade nestes doentes. Esta limitação pode 
ser ultrapassada quando os factores que influenciam o sucesso do enxerto de SCU forem 
conhecidos, sendo crucial o estudo das interacções que ocorrem entre as células 
progenitoras e o seu ambiente (estroma). 
Ainda não estão estabelecidos modelos experimentais empregando estromas a 3 
dimensões (3D) que criam uma analogia ao complexo sistema que ocorre na medula 
óssea (MO) para estudos in vitro, sendo crucial o seu desenvolvimento. 
Neste trabalho procurou-se estabelecer um “nicho” artificial de MO usando um biomaterial 
- Conduit-TCP (3D), juntamente com células precursoras mesenquimatosas humanas de 
medula óssea. Estas células foram diferenciadas a estroma utilizando técnicas clássicas 
de cultivo a longo prazo de medula óssea. Para atingir o objectivo do estudo as células 
CD34+ de SCU foram cultivadas durante cinco semanas neste “nicho” a 3D, que 
demonstrou capacidade durante o tempo de cultura de manter em estado imaturo as 
células progenitoras hematopoiéticas. A produção de colónias (CFU-GM) provenientes 
destes sistemas é superior à produção de colónias quando comparados com o sistema 
de cultivo convencional a duas dimensões, contudo não são diferenças significativas.  
Para complementar a estudos in vitro, desenvolvemos um modelo experimental in vivo de 
forma a avaliar a capacidade de enxerto das células expandidas neste “nicho” artificial, 
para tal implantamos subcutaneamente este biomaterial proveniente de cultivos com 4 e 
5 semanas em murganhos NOD/SCID (animais imunossuprimidos). Na terceira e sexta 
semana após o xenotransplante o grupo onde foram implantados os biomateriais com 
menos tempo de cultivo (4 semanas), apresentavam maior recuperação hematopoiética 
de células humanas (CD45+). Quando se compara com o grupo standard em que o 
“nicho” foi construído in vivo, verificamos um maior nível de células humanas CD45+ no 
sangue periférico nas três semanas pós-transplante e em medula óssea na sexta semana 
pós-transplante, com regeneração medular mielóide (CD13+) para o grupo experimental. 
No grupo standard as células CD34+ foram transplantadas 7 semanas após indução in 
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vivo das células mesenquimatosas a estroma em que se verificou maior enxerto de 
células CD19+ quando as células CD34+ foram transplantadas por via intravenosa, 
contudo quando subcutaneamente transplantadas esta linhagem linfóide diminuía.  
Quando finalizadas as 6 semanas foram realizados estudos ex vivo por histologia, 
imunohistoquímica e imunofluorescência ao biomaterial subcutaneamente implantado e 
aos fémur dos animais dos diferentes grupos.   
No caso dos grupos em que foram transplantados com o “nicho” 
(biomaterial+estroma+célulasCD34+) construído in vitro as células progenitoras 
hematopoieticas conseguiram migrar (homing) deste sistema para a medula óssea dos 
animais.  
Verificou-se regeneração de novo tecido no ConduitTMTCP em que as células 
mesenquimatosas humanas não só contribuíram para a formação do estroma nestes 
implantes como também na angiogénese. Um dado muito interessante foi a confirmação 
de que estas células similarmente as células humanas hematopoiéticas também foram 
capazes de migrar para a medula óssea murina encontrando-se principalmente na zona 
endosteal  
Em resumo, o nicho medular construído in vitro num sistema a 3D permitiu o crescimento, 
diferenciação e migração das células progenitoras hematopoieticas criando uma analogia 
ao ambiente da medula óssea humana, o que permitiu a manutenção e proliferação de 
células hematopoiéticas in vivo e in vitro. Este modelo permite o estudo da hematopoiese 
normal e patológica e sua relação com o estroma.   
 
 
Palavras Chave: Células Precursoras Hematopoiéticas – Sistema a três dimensões – 
Cultivo a longo prazo – Expansão de células CD34+ de Cordão Umbilical – Modelo 
murino NOD/SCID. 
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1 – Stem cells  
 
There is a difficulty to answer seemingly simple questions, as for example How can a 
stem cell be defined? This confusion can be partly attributed to the idiosyncratic terms and 
definitions founded in literature to describe stem cell, like “immortal”, “unlimited”, 
“continuous”, and “capable of extensive proliferation” joining the difficult to have standards 
protocols for identifying, isolating, and characterizing these cells1. 
Stem cells are capable of both self – renewal and ability to differentiate into different types 
of mature cells. Because of these characteristics they play essential roles in 
organogenesis during embryonic development and tissue regeneration2. 
Based on their species and tissue of origin, and their ability to differentiate it is possible to 
sub-classify stem cells in3: 
 Totipotent cells, found in early embryos (1-3 days from oocyte fertilization), can 
originate all the embryonic tissues and placenta; 
 Pluripotent embryonic stem cells (ESC) derived from blastocyts (days 4-14), that 
are compromised into embryonic tissues derived from the inner mass (ectoderm, 
mesoderm, and endoderm); 
 Pluripotent adult stem cells, derived from fetal tissue or cord blood as example, 
can rise only to tissues belonging to one embryonic germ layer (ectoderm or 
mesoderm or endoderm), more limited potential for differentiation. 
 Unipotent cells, giving rise to single lineage cells of certain tissues 
The therapeutic use of ESC is still controversial not only because of their ethical 
problems4 derived of their use but may also carry risk of neoplastic potential development 
(teratomas)5. Unlike the previous, adult stem cells have not shown tumorigenic potential, 
and can be obtained in adequate amounts for autologous or even allogeneic regenerative 
therapy, although they are more difficult to expand6. ESC cells may prove to be ideal for 
creating new organs after passing current ethical and technical minefields, and adult stem 
cells may be more useful for repairing damage to tissues by trauma, disease, or perhaps 
uncomplicated aging. 
Adult stem cells are an essential component of tissue homeostasis, because they support 
ongoing tissue regeneration and maintain the balance between self-renewal and 
differentiation6. The best characterized of them is the hematopoietic stem cell (HSC), 
which is responsible for originating all circulating blood cell types1. Nevertheless, another 
bone marrow stem cell type that has recently attracted notable interest in the scientific 
Introduction 
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community is the Mesenchymal Stem Cell7 (MSC) due to their unique and interesting 
properties, that we will address next  
 
1.1 – Hematopoiesis and Hematopoietic stem cells 
 
Hematopoiesis is a highly orchestrated process defined by the formation, development 
and maturation of all types of blood cells from a common precursor cell – hematopoietic 
stem cells8 (HSC), figure 1. 
Functionally, this extraordinary population was first described in the early 1950s using 
transplantation experiments with mouse models, which describe the ability of these cells 
to engraft and maintain hematopoiesis in lethally irradiated recipients9. Like a stem cell, 
HSC have the unique capacity to self – renewal and the potential to differentiate into 
different kinds of mature cells. However when a bone marrow (BM) or blood stem cell 
transplanted is performed, we can verify that this pool of cells are in different states: on 
one hand a finite-lived population or short term repopulation – HSC (ST-HSC) capable of 
yielding most of the major blood cell types in short time, and the long-term repopulation 
HSC (LT-HSC) that stable through the lifetime of the recipient. The later population is 
typically demonstrated by serial transplantation from cells of the first recipient into 
secondary and tertiary recipients. 
Normally the HSC is located in a specific niche of BM, in a quiescence state (G0) that 
allows the maintenance of long term repopulating cells10.  
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Figure1. Hematopoiesis: CFU – GM, colony forming unit – granulocyte, macrophage; CFU-MEG, colony-
forming unit – megakaryocyte; BFU-E, burst-forming unit – erythroid; CFU-E, colony-forming unit erythroid; 
CFU-Eo, colony – forming unit-eosinophils. 
 
2 – Stem cell Niche: Structure and Function 
 
Normally adult stem cells reside in a specific microenvironment called the “niche” that 
plays a vital role in regulation of stem cell behavior to govern tissue homeostasis under 
diverse physiological and pathological conditions.  
The hypothesis of an evidence for stem cell niche was brought up in 1978 by Schofield et 
al11, describing the physiologically limited microenvironment that supports general genetic 
programs that maintain stem cells natures12. 
 
2.1 – Bone marrow niche 
 
It is well known that adult bone has a unique microenvironment which allows the 
maintenance of hematopoietic stem cells13. Consequently is not unexpected that 
identification and characterization of the stem cells that regulate this process is an active 
field of investigation. 
Hematopoietic
Niche
HSC
Long – term HSC
Short – term 
HSC
Myeloid progenitor
Myeloid 
lineage
Eosinophil
Basophil
NeutrophilMegakaryocyte
Monocyte
Macrophage
Lymphoid 
progenitor
Lymphoid
lineage
Erythrocyte
T cells
B cells
NK cells
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The research on bone marrow stem cells initiated in the 1960s, the pioneering studies in 
vivo by Till and McCulloch14  where they describe classical spleen colony forming (CFU-S) 
assay, allowed to measure the ability of HSC to form large colonies in the spleens of 
lethally irradiated mice, as spleen colony forming units (CFU-S).  
Subsequently, a number of cells fulfilling stem cell properties have been identified in BM, 
besides the hematopoietic stem cells: 
 Endothelial progenitor cells (EPCs); 
 Mesenchymal stem cells (MSCs); 
 Multipotent adult progenitor cells; 
 Marrow – isolated adult multilineage inducible cells.  
Emergence of different definitions of BM niche and discrepancies in published results by 
the scientific community could be explained by the differences in the models employed 
and/or problems in using different experimental strategies when it came to identify these 
cells, leading assigned distinct names.  
The establishment of the stem cell niche hypothesis first presented by Schofield in 1978, 
described the close association of HSC to an environmental niche essential for the 
maintenance of their self – renewal capacity and also regulating the differentiation and 
maturation processes11. When this association is disturbed, the HSC becomes committed 
to specific lines of blood cell development and loses its stem cell property. Consequently, 
BM stromal cells could play an important role in the homeostasis of the hematopoietic 
process. 
Despite the success in identifying some components and signals of the HSC niche, 
validating the general concept that environmental factors, including soluble signals, 
specific cell-cell and cell-matrix interactions, as well as structural cues are vital for stem 
cell maintenance and function, the complete understanding of the extrinsic and intrinsic 
signals that influence the choice between self-renewal and differentiation of HSC remains 
elusive. That is due to the limited availability of appropriate ex vivo models which could 
mimic the complex niche organization15.  
During human embryogenesis the HSC are first presented in the yolk sac and in the aorta-
gonad-mesonephros region, followed by fetal liver and spleen. With the beginning of 
gastrulation and organogenesis stem cells migrate and colonize tissue-specific niches, 
residing as a population of self – renewing cells, this is the most active period for the 
development migration/trafficking of stem cells16.  
The hematopoietic niche on human adults is generally confined to the BM, and  consist of 
diverse cells of the osteoblastic lineage17 indifferent developmental stages that includes 
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preostoblasts, osteoblasts, osteocytes, together with collagen fibrils, and mineral deposits 
such calcium and phosphate18. In addition, the bone cavity also contains fibroblasts, 
macrophages, endothelial cells, and adipocytes. 
It is difficult to discern the relative importance of each of these cells to maintain the 
hematopoietic niche. Only in recent years with the advent of mouse genetic models and 
live microscopy that permits to visualize the exact location, cellular composition, and 
associated molecular signals of the HSC niche decreased the gap of information, but the 
mechanism is still far from being fully understood.  
At present, at least two distinct niches have been identified in the BM, responsible to play 
central roles in regulating stem cell proprieties19: the osteoblastic niche and the vascular 
niche20. Different experimental studies showed that according to HSC level of lineage 
commitment, the spatial distribution is distinct15. Precursors are mainly located in the 
central marrow region close to the sinusoids (vascular niche) that allows differentiation 
and ultimately mobilization into the peripheral circulation, and long-term HSC are 
predominantly localized in the endosteal region (trabeculae), in close contact with 
osteoblasts (osteoblastic niche), where the signaling events between these types of cells 
are crucial in maintenance and activation of stem cells15, 18, 21, figure 2.  
Osteoblastic cells also secrete cytokines that regulate stem cell function, including 
granulocyte–colony-stimulating factor (G-CSF), M-CSF, GM-CSF, interleukin-1 (IL-1), IL-
6, among others17, 18 
HSC trafficking, proliferation and survival is controlled by a complex signaling network 
produced by osteoblasts induced through the contact with HSC. Among them, Notch and 
Wnt signaling as well as the SDF-1/CXCR4 axis, are key components of the system.   
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Figure 2. Model of hematopoietic stem cells niche: In bone marrow the primitive HSC reside either next to 
osteoblasts on the endosteal niche (compartment B), where most primitive and quiescent HSC reside, and in 
the vascular niche, where more committed HSC (ST-HSC) can be found adjacent to endothelial cells of 
sinusoidal vessels (comportment A), from where they can be released from the vascular niche into the 
systemic circulation. 
It has been demonstrated that primitive hematopoietic cells in the BM are under a hypoxic microenvironment 
implying low oxygen levels are important in the maintenance of normal stem cell function
22
. 
 
2.2 Mesenchymal Stem Cells 
 
Mesenchymal stem cells (MSC) are the precursor of most stromal cells of BM 
microenvironment, and thus a key component of the hematopoietic niche23.  
The first demonstration of MSC in BM was in the early 1970´s, by a pioneer work of 
Friedenstein and colleagues24 that described a population of spindle-shaped cells in vitro 
were able to adhere to plastic surfaces and  form colonies designed as fibroblast colony-
forming units (CFU-F). This population represents only about 0.01-0.001%25 of the total 
mononuclear cell (MNC) fraction in adult human BM, a proportion that varies with age and 
health26. 
MSC
Chondrocyte Osteoblast Fibroblast Adipocyte Myocyte ?Endothelial cell
LT - HSC
A
B
OsteoblastOsteoblastOsteoblast
Adipocytes
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MSC are not exclusively found in  BM. Cells with MSC characteristics can be present in 
others tissues and organs such as fat, umbilical cord blood, placenta, muscle, liver or 
lung27.  
This population in the recent years has become objective of great scientific interest given 
their potential capacity to differentiate in mesoderm-type cells, including fibroblasts, 
osteoblasts, chodroblasts, and adipocytes28, and for their in vitro expansion without 
compromising its genetic stability29. In addition, MSC have strong immunomodulatory 
activity both in vitro and in vivo, and are themselves immune-privileged30,31 These cells 
can escape from host allogeneic response because they appear to be poorly 
immunogenic, since express low levels of major histocompatibility complex (MHC) class I 
and do not express MHC class II molecules32.  
Moreover, MSC do not express co-stimulatory molecules such CD40, CD80 or CD86 
which also involved in the activation of T cells. In addition, they release bioactive 
molecules that were shown to inhibit not only T cells, but also B cells, NK cells, and 
monocyte-derived dendritic cells25. 
Some studies have demonstrated that the inhibitory effects of MSC in vitro were directed 
mainly by the level of cell proliferation, the T-cells are arrested at G1 phase, the MSC 
removed from the cultures allows the T-cells to restore the ability to produce IFN- in 
response to subsequent stimulus33.   
In the case of dendritic cells, MSC induce to tolerogenic phenotype since dendritic cells 
cultivated in the presence of these cells produce more IL-10 and inhibit their differentiation 
from monocytes34 
 
2.2.1 Mesenchymal stem cell isolation, expansion and characterization 
 
The first step to isolate MSC is generally the use of density centrifugation techniques to 
obtain the mononuclear fraction of BM35. Due to their characteristic plastic adherence, 
MNC are plated in culture flasks containing a standard culture medium and generally 10% 
of serum, although expansion media can be modified to improve the cell yield36. Thus, 
MSC are purified through successive passages where hematopoietic mononuclear cells 
are washed-out with the medium replaced. MSC has a characteristic spindle-shape in 
vitro, MSC was initially identified by a combination of this in vitro morphology, together 
with a characteristic immunophenotypic pattern and the demonstration of their in vitro 
multilineage differentiation potential37, 38. Despite the different efforts to extensively 
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characterize MSC surface immunophenotype, no single and specific MSC marker has 
been identified to date, table 1. 
 
Table1. Surface antigen frequently identified during MSC isolation38. 
Human MSC 
Marker type Surface antigen 
Positive Stro-1; CD13; CD29; CD44; CD73; CD 105 and CD106 
Negative CD11b; CD31; CD34; CD45; CD117 
Variable Sca-1; CD10; CD90; Flk-1  
 
 
In order to minimize the increasing difficulty to compare and contrast study outcomes, the 
Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular 
Therapy proposed, in 2006, the minimal criteria to define MSC based on phenotypic and 
functional characteristics39. 
 
 Must be plastic – adherent when cultured in vitro under standard conditions; 
 Lack of expression of hematopoietic markers: CD45, CD34, CD14 or CD11b, 
CD79α or CD19 and HLA class II and express a specific pattern of surface antigen 
expression, namely CD105, CD73 and CD90; 
 Must demonstrate under standard in vitro conditions the multipotent differentiation 
potential into osteocytes, adipocytes and chondrocytes (three different lineages) 
 
2.3 – Three dimensional systems (3D) 
 
In humans bone marrow is the principal and permanent hematopoietic organ where 
specialized microenvironments reside, called niches, regulate HSC. Anatomically, BM 
stroma includes virtually all nonhematopoietic cells types40 reorganized in appropriated 3D 
architecture where the stromal cells and the extracellular matrix provide a physical and 
functional support that also regulates cell migration, proliferation, and differentiation 
through cell-to-cell and cell-to-substrate interactions41, figure 3.  
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Figure 3. Schematic illustration of the parameters required to culture HSC in a 3D system that mimic 
an artificial niche. The bulk properties of the 3D Scaffold co-cultured with MSC in appropriate culture 
conditions try to recreate the physiological complexity of a stromal supportive tissue
41
.  
 
Recently, several studies have tried to mimic the BM microenvironment by 3D culture 
systems42. They have attempted to recreate the native BM environment by the addition of 
cytokines, growth factors or by the presence of co-cultured stromal of feeder cells. 
Employing 3D cell culture systems can induce more intensity cell-to-cell contacts between 
HSC and stromal cells which appear promising to produce the appropriate developmental 
niche for stem cells, and the growth and differentiation capacity compared to 2D 
cultures43-46.  
 
3 – Hematopoietic stem cell transplantation 
 
Since the first successful hematopoietic cell transplant in the early 1950s, hematopoietic 
stem cell transplantation (HSCT) has been employed as an effective strategy to treat not 
only several hematologic malignancies but also congenital or acquired defects of 
hematopoiesis or immune function47. HSCT is generally classified according to the source 
of the cells into autologous, syngeneic or allogeneic HSCT.  
Mobilized peripheral blood (PB) is the most common source of HSC for transplantation48, 
since the procedure is easier and the donor can avoid entering in the operating room, 
3D Scaffold Properties:
- Architecture and support; highly
pores interconnect structure to
cell matrix and cell-scaffold
interactions; biocompatible;
provide surface chemistry for cell
attachment, proliferation and
differentiation; mechanical
properties for implantation.
Culture 
conditions: eg, 
bioreactors
Co-culture of stromal cells 
(MSC): -structural organization, 
cell-cell interaction, cytokine 
secretion and self regulation
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however the engraftment is shorter with PB when compared to BM49. Nevertheless, the 
use of PB is associated with a higher rate of graft-versus-host disease (GVHD), the main 
complication of allogeneic HSCT, due to the higher content of T-cells within the mobilized 
PB-graft50.  
In addition to the problems described from allogenic HSCT, the HLA-matched sibling 
donor is also a problem because just only 30% of patients have a potential sibling donor 
with adequate match with patient´s HLA loci. This problem is increased in non-caucasian 
patients51.    
 
3.1 – Umbilical cord blood stem cell transplantation 
 
Since the first use of human umbilical cord blood (UCB) for HSCT in 198952, this modality 
has notably increased its importance due to the higher number of patients that are 
candidates for transplantation, and the lack of a suitable donor, as it has been already 
mentioned. Among the advantages53 of UCB HSCT is the higher immunotolerance of the 
graft, so that a less stringent HLA-match is permitted, compared to BM or PB 
transplantation, without a higher incidence of GVHD. Nevertheless, UCB transplantation 
has the disadvantage of a delayed hematopoietic engraftment with a higher rate of graft 
failure, which is associated to an increased transplant-related mortality, mainly due to 
infection54. Strategies to enhance UCB engraftment include the in vitro expansion of CB 
cells, transplant of 2 UCB units, co-transplant of CD34+ cells from an haploidentic related 
donor, the co-transplant of MSC or the administration of the UCB progenitors via 
intrabone. Most of the above mentioned strategies are in an experimental phase55-57. 
 
3.2 – Mesenchymal stem cells and hematopoietic stem cell transplantation 
 
MSC of BM origin are responsible to recycle the pool of most cellular components that 
supply hematopoietic microenvironment niche, including fibroblasts, osteoblasts, and 
adipocytes. In addition, they provide hematopoietic growth factors, facilitate cell-to-cell 
interaction, and elaborate matrix proteins that play a role in the regulation of 
hematopoiesis. 
Despite an intensive preparation regimen, an adequate cell dose and complete donor 
chimerism poor haemopoietic function can be observed after HSCT58, 59. One of the critical 
points in haematopoietic regeneration following HSCT is the capacity of the recipient 
recovery the spatial organization of the bone marrow micro-environment10.   
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MSC contribute in the context of HSCT60  since can directly and indirectly regulate and 
controlled the maintenance of HSC. The MSC express a variety of α integrin and β – 
subunits and their monovalent associations that constitute receptors for extracellular 
matrix components including collagen, laminin, fibronectin and vitronectin who regulate 
the organization of the extracellular matrix25. In co – culture experiments, MSC form cell 
clusters with HSC, including megakaryocytes and osteoclast progenitors, providing a 
physical support for HSC61.  
MSC also modulate the immune response in vitro and in vivo, interacting with a broad 
range of immune cells including T-lymphocytes, B-lymphocytes, NK and dendritic cells. 
For all these properties, the therapeutic use of MSC is being explored in the HSCT setting 
for a number of complications, including graft failure or acute and chronic GVHD62.  
 
3.3 – Ex vivo models to study hematopoiesis 
 
The first assays to study stem cell biology were introduced by Bradley and Metcalf with 
the semisolid culture system-colony-forming assay63. The primary aim of these assays 
was to obtain information on the developmental stages and differentiation potentials of 
HSC and also visualize their dynamics and kinetics. 
However these methods do not recognize the presence of cells which have not matured 
enough to exhibit the characteristics of mature cells,  for the temporary hematopoiesis (2-
4 weeks) despite attempts to supplement with nutrients and cytokines, and most primitive 
stem cells fail to survive and proliferate64. 
When cultured in a suitable semi-solid matrix, such as methylcellulose supplemented with 
nutrients and cytokines, HSC or hematopoietic progenitors called colony-forming cells 
(CFCs) proliferate to form discrete cell clusters or colonies.  Colony types include colony-
forming unit-erythroid (CFU-E), burst-forming unit-erythroid (BFU-E), CFU-granulocyte, 
macrophage (CFU-GM) and CFU granulocyte, erythrocyte, macrophage, megakaryocyte 
(CFU-GEMM), the later are most commonly used, clinical transplantation, to provide a 
quantitative, high-throughput method to accurately measure HSC or hematopoietic 
progenitor clonogenic capability65. 
In attempts to more closely mimic hematopoiesis, Dexter et al. (in 1970s), developed the 
long-term bone marrow derived stromal culture who supported the production for several 
weeks of HSC66. 
Long-term culture initializing cell (LTC-IC) assay and Cobblestone area forming cell 
(CAFC) assay has been developed to recognize the presence of immature HSC in vitro.  
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LTV-IC cultures were developed with the aim to support the continued production of 
myeloid cells, and subsequently for the production of lymphoid cells67. The primitive 
progenitors can persist for more than 5 weeks and generate secondary CFU-C, while the 
committed progenitors present in the culture-flask are removed with medium changes, 
and susceptible of being assayed by semisolid cultures. This assay is a powerful 
procedure to quantify and distinguish cells at discrete stages of early hematopoietic cell 
differentiation68. 
The CAFC can be scored sequentially assessing the percentage of confluence of the 
stromal layer and observing the presence of cobblestone areas, that represents areas of 
active in vitro hematopoiesis69. 
 
3.4 – In vivo models to study hematopoiesis 
 
Considering that the in vitro assays can not sufficiently assess the engraftment potential of 
human HSC, the use of murine models of transplantation allows the study of basic 
principles of stem cell biology including immunophenotype, homing ability, engraftment 
kinetics, cytokine responsiveness and radiation sensitivity of repopulating cells. 
The classical experiments of bone marrow transplantation were developed in the early 
1950s showing that the infusion of BM from a donor could protect the recipients after 
lethal irradiation.  
Human HSC activity can be tested by transplantation into immunodeficient mouse strains, 
which are unable to reject xenogenic cells. Principally, non-obese diabetic/severe 
combined immunodeficient – LtSz-scid (NOD/SCID) mice have proven to be a reliable 
recipient for detecting human hematopoietic – repopulating cells that differentiate into 
multilineage mature cells self-renew in mice. This is owed to their complete deficiency in 
alloreactive lymphocytes especially NK cells70. The level of human engraftment, in this 
model, after xenotransplantation of BM and UCB is higher (10x) than the classical 
transplants using SCID mouse. 
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Studies using the NOD/SCID/beta-2- microglobulin-null mouse strains have demonstrated 
a hierarchy of human repopulating cells supporting successive waves of human 
hematopoiesis in the mice. More recently assays show others models like, NOD/SCID/c-/- 
mice have been used as improved recipients for human HSCs, capable of complete 
reconstitution with human lymphocytes, even in the absence of additional human tissues. 
Even more promising has been the use of newborn mice with a profoundly impaired 
immune system (Rag-2-/-C-/-), which results in a reproducible production of human B- and 
T-lymphoid and myeloerythroid cells71.  
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Hematopoietic stem cell transplantation (HSCT) is used to treat several disorders of the 
immunohematopoietic system. The conditioning regimen is toxic for hematopoietic stem 
cells (HSC) but also for the microenvironment.  
A balance between the maintenance of the stem cell pool and the differentiation of HSC is 
mediated by soluble and membrane-bound cytokines, extracellular matrix components, 
and direct cell-to-cell contact.  
Umbilical cord blood (UCB) units are being increasingly used for hematopoietic stem cell 
transplantation. The main limitation of UCB transplantation is a delayed engraftment. 
Thus, an adequate understanding of UCB stem cell homing and lodging in the 
hematopoietic niche is important to implement the procedure in the future.   
Mesenchymal Stem Cells (MSC) are the key component of the hematopoietic niche since 
they are progenitors of most of the cell components of the BM microenvironment 
(osteoblasts, adipocytes, fibroblasts, etc). MSC regulate the niche both by secreting 
multiple soluble factors and by cell-to-cell contact.  
In the present work we want to develop an in vitro 3D-model of human stroma using MSC 
and a biocompatible scaffold of ConduitTM-TCP, able to maintain HSC proliferation and 
differentiation. Then, we will establish an in vivo model of human hematopoiesis by 
transplanting this humanized 3D niche subcutaneously into immunocompromised mice 
and further evaluate its ability to support hematopoiesis by administering CD34+ cells 
from UCB either IV or directly into the ectopic niche. 
 
Specific objectives: 
 
 To evaluate in vitro if human MSC and Conduit-TCP reproduce a functional stroma 
that is able to support the maintenance and proliferation of human HSC from UCB; 
 
 To assess if the latter 3D-BM niche developed in vitro (MSC+Conduit-TCP+hHSC) 
when implanted subcutaneously in immunocompromised mice supports in vivo the 
homing and engraftment of human HSC; 
 
 To evaluate if the 3D-BM niche (MSC+Conduit-TCP) induced in vivo supports the 
homing and engraftment of hHSC administered either intravenously and directly 
next to the subcutaneous implant. 
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All the experiments of the present work were performed in the Cell Therapy Lab of the 
Hematology Department of the University Hospital and in the Animal Care Facility of the 
University of Salamanca. 
 
1 – Human cell samples  
 
Human cell samples were obtained from bone marrow (BM) aspirates of healthy donors 
collected at the University Hospital of Salamanca and fresh human umbilical cord blood 
(UCB) from the Barcelona Blood and Tissue Bank, strictly following their standard ethical 
criteria.  
All samples from volunteer donors were obtained/proceeded after written informed 
consent had been obtained, in accordance with and approved by the Ethics Committee of 
the University Hospital of Salamanca.   
 
Table 2. Characteristics of human samples used for the in vitro and in vivo studies   
M: Male; W: Woman *results are expressed by the median (range); NI – No identify  
 
2 – Animals 
 
To perform in vivo xenotransplantation assays a total of 18 six to eight weeks old female 
NOD.CB17Prkdcscid/NcrCrl* (NOD/SCID) mice were purchased from Charles River 
Laboratories (Barcelona, Spain). 
Animals were housed in microisolator cages with a maximum of 6 mice per cage in the 
animal facility of the University of Salamanca, maintained under constant conditions of 
temperature and humidity, 12 hours dark / light cycles, in sterility and asepsis ideals, and 
fed ad libitum with autoclaved food and water. They were maintained for at least one week 
before any experimental procedure. Those were performed following the Spanish and 
European Union guidelines (RD 1201/05 and 86/609/CEE, respectively) and after the 
approval of the local Bioethics Committee of the University of Salamanca
 
 
 BM Samples 
(n=3) 
UCB Samples 
(n=6) 
Age* 37,5 (29-46) NI 
Sex(M/W) 3/1 NI 
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3 - MSC isolation, expansion and characterization 
 
3.1 Bone marrow aspirates 
 
Bone marrow (BM) aspirates were obtained from the posterior iliac crest aspiration under 
local anaesthesia from 6 healthy adult donors according to standard institutional 
procedures (University Hospital of Salamanca, Spain). BM were collected in sterile tubes 
(Venoject; Terumo®) with free heparin (without additives – 5000U/ml; Seromed Biochrom KG).  
 
3.2 BM – MSC isolation and expansion 
 
After confirming the absence of BM clots, samples were diluted 1:3 with Hanks Solution 
(Hank’s Balanced Salt Solution, Gibco®, InvitrogenTM). The low-density BM mononuclear cells 
(MNC) were separated by density gradient centrifugation at 500g for 30 minutes on 
solution of high density with low viscosity and low osmotic pressure72 – Ficoll (Ficoll-Paque, 
density:1.077k, GE Healthcare BioSciences, Buckinhampshire, UK). Then, cells were washed twice 
with Hanks and counted. BM-MNC were seeded at a density of 1x106 cells/cm2 on plastic 
culture flasks (Corning Incorporated, Corning, NY, USA) with expansion medium consisting on 
DMEM (Dulbecco’s modified Eagle’s medium–low glucose - Gibco, Invitrogen, Paisely, UK) 
supplemented with 5% platelet lysate36, heparin (200 IU/ml) and 1% 
penicillin/streptomycin (105U/ml/105µg/ml - Gibco, Invitrogen, Paisely, UK) and cultured at 37ºC 
and 5% CO2 in a humidified atmosphere. Platelet lysates (PL) were obtained from the 
blood Bank of the University Hospital of Salamanca (units that were discarded 
immediately after their expiration date) were pooled in a single culture supplement, frozen 
at -80ºC and subsequently thawed at 37ºC to obtain containing platelet-released growth 
factors from pooled platelet. Culture medium was replaced every 3-4 days and non-
adherent cells were removed. By this procedure, MSCs were isolated due to their 
characteristic adherence to plastic surfaces. BM-MSCs cultures were maintained until 
they reached 70-80% of confluence. Afterwards, cells were washed with phosphate buffer 
saline (PBS)(GIBCO®, Invitrogen™ Corporation, Paisely, UK) and harvested with 0,05% Trypsin – 
EDTA (Gibco, Invitrogen Paisely, UK) for 5 minutes at 37ºC. The mixture was centrifuged at 
300g for 10 minutes and supernatant was discarded. Cells were resuspended in 1 mL of 
expansion medium, counted and replanted into new flasks at 5x103 cells/cm2. 
For MSC characterization, third passage cells were analyzed by flow cytometry following 
the minimal criteria set by International Society of Cellular Therapy39, which also included 
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the demonstration of the multilineage (osteogenic, adipogenic and chondrogenic) 
differentiation potential. 
 
Figure 4. Scheme of BM – MSC isolation, expansion and characterization 
 
3.3 Immunophenotyic characterization of MSC 
 
At passage three, MSC were harvested as previously reported and resuspended in 100µL 
of PBS for their characterization by flow cytometry. Approximately 5x105 cells per 
polystyrene tube (Falcon, Becton Dickinson Biosciences, San Jose, CA, USA) were incubated for 15 
minutes with combinations of four-color conjugated-monoclonal antibodies (Table 3) and 
then washed and centrifuged 5 minutes at 700g with PBS for eliminate the excess of 
antibodies.  
Monoclonal antibodies were conjugated with fluorescein isothiocyanate (FITC), 
phycoerythrin (PE), phycoerythrin-cyanine 5 (PerCP Cy5) and- allophycocyanine (APC) 
and combined as follows: 
 
Table 3. Fluorochrome-conjugated antibodies for immunophenotype characterization of MSC of 
the samples 
Tube Antibodies Quantity 
Tube 1 Control - 
Tube 2 CD90/CD166/anti-HLA-DR/- 2µL/10µL/10uL 
Tube 3 CD34/CD73/CD45/CD105 10µL/10µL/10uL/3µL 
Tube 4 CD44/CD14/CD19/- 10µL/10µL/10uL 
The control tube was done to correct the high auto fluorescence of the MSC (absence of antibody) 
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Table 4: Fluorochrome-conjugated antibodies 
for immunophenotype characterization of 
hMSC 
 
 
 
 
 
 
 
 
The measurements were performed on a FACSCalibur equipped with four-color option 
(Becton Dickinson Biosciences, San Jose, CA, USA) and CellsQuest software (Becton Dickinson) was 
used for acquisition of a minimum of 50,000 events for each condition. Calibration 
procedures were perfomed before the acquisition of the records using previously 
established protocols provided by the Flow Cytometry Unit (University Hospital of Salamanca). 
Data were analyzed using the Infinicyt program (Cytognos, Salamanca, Spain). 
 
3.4 Evaluation of Differentiation Capacity 
 
3.4.1 Osteogenic differentiation – At fourth passage MSCs were plated at a concentration 
of 5,000 cells/cm2 in a 9.6 cm2 slideflask (Nunc, Denmark) with expansion medium to 
achieve 80% of confluence. Then cells were cultured in osteogenic medium (NH Osteodiff 
Medium; Miltenyi Biotec, Bergisch Gladbach, Germany) to induce there in vitro differentiation. 
Medium was replaced every 3-4 days during 10 days. At this time point osteogenesis was 
assessed by alkaline phosphatase activity detection. Detection of alkaline phosphatase 
expression was performed by staining with NBT/BCIP solution (Nitroblue tetrazolium chloride/5-
bromo-4-chloro-3-indolyl-phosphate - Roche, Basel, Switzerland) for 20-30 minutes and contrasted 
with hematoxylin (Merck KG1A, Darmstadt, Germany).  
 
3.4.2 Adipogenic differentiation – Similarly to osteogenic differentiation, cells were grown 
in a slideflask until reached 80% of confluence, and subsequently incubated with the 
specific differentiation medium  (NH Adipodiff Medium; Miltenyi Biotec) for 21 days replacing  the 
culture medium twice a week. For adipocyte detection cells were stained with Oil-Red-O 
 Fluorochrome Origin 
CD90 FITC  
 
 
all from Becton 
Dickinson 
Biosciences, San 
Jose, CA, USA 
CD44 FITC 
CD34 FITC 
CD14 PE 
CD19 PerCP Cy5.5 
CD45 PerCP Cy5.5 
CD73 PE 
Anti-HLA-DR PerCP Cy5.5 
CD166 PE 
CD105 APC R&D Systems, 
Minneapolis, MN, 
USA 
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solution (Certistain Merck KG1A, Darmstadt, Germany). Adipogenesis was confirmed by the 
observation of the accumulation of neutral lipids in fat vacuoles.  
 
3.4.3 Chondrocyte differentiation – 5x105 cells were placed in a 15 mL polypropylene tube 
(Corning Incorporated, Corning, NY, USA) and centrifuged. Pellet was cultured in 500µL 
chondrogenic medium (NH Chondrodiff Medium; Miltenyi Biotec) for 21 days changing the 
medium twice a week. Over this time, pellets were embedded in paraffin, cut into 5-µm 
sections and chondrocyte differentiation was demonstrated by methylene blue staining. 
During the evaluation of the differentiation potential to osteoblast, chondrocyte and 
adypocytes also control cultures were used. In controls the MSCs were maintained in the 
same conditions as previously described but using only expansion medium. All cultures 
were incubated at 37ºC in a 5% CO2 humidified atmosphere. 
Slides were observed with an Olympus BX41TF microscope (Olympus Optical Co.,Tokyo, 
Japan).  
 
4 – Transfection of MSC with lentiviral vectors (LV)  
 
4.1 Plasmid DNA (pDNA): 
 pLV-CMV-hGluc-Ires-CFP (6094bp) LV vector containing the Gaussia luciferase 
(Gluc) and the Cyan Fluorescente Protein (CFP), under the human 
cytomegalovírus (CMV) immediate-early promoter. 
 psPax2 (10703bp) packaging vector containing viral polimerase and packaging 
genes. 
 pLV-VSVG (5821bp) envelope vector encoding the G protein of the Vesicular 
Stomatitis Virus (VSV-G).  
All vectors contain resistance to the antibiotic ampicillin that was used for bacterial 
selection, as indicated next. 
 
4.2 Production and isolation of pDNA   
 
The pDNA were produced using Escherichia coli DH5α following a transformation 
protocol, that consist in create a heat shock73, incubating the bacteria and the DNA 
together on ice, placing them briefly at 42ºC and then back on ice. 
Then bacteria were planted on Luria Bertini (LB) agar plates containing ampicillin 
(100mg/ml) and maintained overnight at 37ºC.  
Material and Methods 
 
     23 
 
Only transformed bacteria that contain the plasmid could express beta-lactamase and can 
survive on the ampicillin plates, than was allowed their growth and consequently high – 
copy plasmid DNA. Plasmid purification was performed according to the QIAGEN® 
Plasmid Purification kit protocol (QUIAGEN). The concentration of purified pDNA solutions 
was assayed by spectrophotometry at 260 nm using a NanoDrop equipment and DNA 
integrity was confirmed by DNA agarose gels stained with ethidium bromide. 
 
4.3 Production of lentiviral vectors (LVs) 
  
Self-inactivating LVs containing the enhanced cyan fluorescent protein (eCFP) gene were 
generated by co-transfection the 293T cells using calcium phosphate transfection 
protocol. 
2x106 293T cells were seeded in 15 cm diameter cultures dishes (Falcon, Becton Diskinson 
Bioscience, San Jose, CA, USA), maintained with DMEM medium containing 10% fetal calf 
serum (FCS) (BioWhittaker, Lonza, Verviers, Belgium) and penicillin/streptomycin (pen/strep) in 
5% CO2 at 37° C incubator until  they reached 40-50% of confluence (approximately 24 
hours).  
For 293T transfection, a total of 35µg of pDNA was added to each culture dish. The 
transfection medium included pLV-VSVG, psPax2 and pLV-CMV-hGluc-Ires-CFP vectors 
in calcium phosphate (for the DNA precipitation) and, buffer 2x HeBS* diluted in DMEM 
with penicillin/streptomycin. 
 
  
 
 
 
 
  
 
 
   
 
Figure 5. Second generation packaging construct of Lentivirus in 293T cells  
 
*2xHeBS: 200mM NaCl, 10mM KCL, 1,5m MNa2HPO4.2H2O, 12 mM dextrose and 50mM HEPES in milliQ 
water. 
Transfer plasmid; 
Envelope gene 
A pseudotyping plasmid encoding the G protein of 
the Vesicular Stomatitis Virus (VSV-G)  
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Medium containing lentiviral supernatant was collected after 24 and 48 hours (in a 5% 
CO2 incubator at 37ºC) pooled, filtered through a 0.45 mm pore filter, and frozen at -80ºC 
until used.  
Virus titration was calculated by subsequently virus dilutions (Figure X) on a 6-well plate 
with 293T cells.  
 
 
 
 
 
 
 
Figure 6. Different concentration of virus in the culture medium used for virus titration. 
WD – without dilution                                            
 
After 3 days of culture (5% CO2 at 37ºC), the efficiency of transduction was determined by 
flow cytometry analysis of CFP expression on 293T cells as previously described. Data 
were analyzed using the Infinicyt® software calculating the percentage 293T cells in the 
first fluorescence channel. Titer was calculated using the following formula: 
 
Cell concentration at the day of transduction x virus supernatant dilution x % CFP-positive cells 
                                                                  Total volume. 
 
 
4.4 Transduction of MSC 
 
Passage 2 MSC were grown in a culture flask until subconfluence (around 50%) was 
observed. Then expansion medium was replaced by LV supernatants diluted 1:8 with 
DMEM with 10% FCS and peni/strep, resulting in a multiplicity of infection (MOI) of 1. To 
increase the efficiency of transduction 8µg/mL polybrene (hexadimethrine bromide, Sigma-
Aldrich, Steinheim, Germany) were added.  
After 24 hours, transduction medium was again replaced by fresh expansion medium 
(DMEM 10% FBS and peni/strep). Transduced hMSCs were maintained in standard 
conditions until they reached 90% of confluence. Cells were harvested and CFP+ hMSCs 
were analyzed by flow cytometry to determine transduction efficiency.     
 
control WD 1/3 
1/9 1/27 1/81 
  Material and Methods 
 
25 
 
5 - Isolation and characterization of hematopoietic Stem Cells (HSC - CD34+) from 
UCB 
 
A total of 10 fresh human UCB units were obtained from full-term normal delivers after 
parental donor consent, supplied by Barcelona Blood and Tissue Bank when were 
discarded for cryopreservation due to low number of cells.  Heparinized cord blood was 
diluted (1:2) in isotonic 0,9% sodium chloride (sterile saline solution) and UCB 
mononuclear were separated by Ficoll density gradient and washed twice with saline 
solution. Then MNC were counted and CD34+ progenitor cells were sorted by magnetic 
labeling using the human CD34 MicroBead Kit (Miltenyi Biotec) in accordance with the 
manufacturer’s protocol. The purity of CD34+ cells, after the isolation, was evaluated by 
flow cytometry using FITC-conjuG1ted CD34 (Becton Dickinson Biosciences, San Jose, CA, USA). 
 
6 – Scaffold characteristics  
 
Conduit® TCP Granules (DePuy Johnson & Johnson, Warsaw, USA) are commonly used as a 
substitute for bone defects repairment because is similar to the mineral phase that 
comprises 70% of adult human bone. It consists of a synthetic porous ceramic composed 
of tricalcium phosphate beta (β-TCP, Ca3(PO4)2), forming 1.5-3mm diameter granules with 
interconnected pores that occupy 70% of volume and average pore diameter between 1 
and 600μm. This sacaffold is resorbed through cell mediated events that are involved in 
the normal remodeling cycle of bone74. 
 
7 - In vitro cell culture experiments 
 
Three groups in vitro were constituted to evaluate in vitro if the 3D-BM niche constructs 
(MSC+Conduit-TCP+HSC) were able to support HSC. On in vitro group 1 (G1), 
approximately 2x105/mL MSC-CFP+ on 3rd passage were seeded onto a six well culture 
plate with 3 mL of expansion medium. On in vitro group 2 (G2) the same proceeded was 
done, but with the scaffold (16 Conduit-TCP granules per well). Were maintained in 
cultured on a incubator (37ºC with a humidified 5% CO2 atmosphere) changing culture 
medium twice a week, until 80% of confluence was achieved. Then half of the granules 
(containing MSC attached inside) were transferred into new culture plates to have MSC 
growing in a real 3-D structure, while the other half remained on the original wells, 
constituted the in vitro group 3 (G3) (Figure 6)  
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7.1 Long-term bone marrow culture (LTBMC) 
 
When MSC-CFP+ achieved the confluence, expansion medium was changed by LTBMC* 
medium for 2 weeks to induce stromal differentiation, changing the medium twice a week. 
This medium can support both stromal cell-containing feeder layer (MSC), as well as a 
number of hematopoietic cells generated. 
With a stroma formed, 2x105/mL CD34+ cells from UCB were added for each well in the 
three groups and maintained in culture with LTBMC for 5 weeks. Formation of adipocytes, 
cobblestone areas and the stroma layer confluence was analyzed weekly75.      
Also half of the supernatant was weekly removed and replaced by fresh LTBMC medium. 
The harvested non–adherent cells were counted and 5x103 cells were planted in a 24-well 
culture plate  (Costar, Corning NY, USA) with 0,5 mL of methylcellulose medium – Methocult 
H4534 (Stem Cell Technologies, Grenoble, France) to quantify the progenitor cell Colony Forming 
Unit–Granulocyte/Macrophage (CFU-GM). These cultures were incubated in a humidified 
atmosphere at 37ºC with 5% CO2. After 14 days, CFU-GM colonies were scored with an 
inverted microscope following standard criteria for colony counting. Results were 
expressed as the number of CFU-GM per 105 cells seeded and the total number of CFU-
GM present in the culture. 
 
8 – In vivo experiments 
 
To assess if the in vitro 3D-BM niche constructs were able to support in vivo homing and 
engraftment of HSC a xenotransplant murine model using female NOD/SCID mice was 
used. Animals were exposed to 300-cGy total body irradiation from a Cesium 137 source 
(Gammacell-200, Nordion International, Ottawa, ON, Canada) six to eight hours before the transplant. 
All the experimental procedures in the xenotransplantation setting were performed  under 
anesthesia with a mixture of 90mg/kg dose of ketamine (Imalgène 500, Merial, Lyon, France) 
and 10 mg/kg of xylazine (Rompun 2%, KVP Pharma Healthcare, Kiel, Alemania) administered 
intraperitoneally.  
 
 
 
*LTBMC: IMDM (Iscove´s Modified Dulbecco´s Medium, Gibco
®
, Invitrogen
TM
 Corporation, Paisely, UK) to an 
osmolarity of 350mOsm/l supplemented with horse serum (PAA Laboratories, Pasching, Austria), 1% 
Hydrocortisone and 1% antibiotic. When mixed was filtered, aliquoted and frozen at -20ºC until use.  
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8.1 Study design  
 
A total of 18 animals divided into 3 groups (n=6/group) were used to assess the level of 
human engraftment using MSC with Conduit® TCP Granules as bone marrow niche and 
CD34+ cells from UCB as hematopoietic progenitor cells.  
After anesthetized, each mouse was shaved and cleaned with 70% ethanol, three small (6 
mm) incisions were made on the dorsum and a subcutaneous pocket was made between 
the dermis and the underlying tissue where were implanted the scaffolds, the incisions 
were sutured with nylon. 
 
In vivo Group 1 → 2x106MSC/ml were maintained in contact with the scaffold (2-3 
ConduitTM-TCP granules placed in a 6-well plate) for 2 hours in the incubator at 37ºC, to 
facilitate the adhesion of the cells. Then, the mixture was subcutaneously implanted in the 
mice.  
MSC on the scaffolds were in vivo induce to stroma during 7 weeks. Past this time the 
mice were irradiated with a sublethal dose (3Gy) as previously described, and injected 
either intravenously (IV) in the lateral tail vein or subcutaneously (SC) into the scaffold, 
2x105 CD34+ cells/mouse resuspended in a total volume of 200µl of PBS.  
Three and six weeks after transplantation samples from peripheral blood (PB) and bone 
marrow (BM) were obtained for human hematopoietic engraftment by flow cytometry. 
 
In vivo Group 2 and 3 → NOD/SCID mice with 7 weeks were irradiated with a sublethal 
dose (3Gy) as previously described, and 6 hours after the irradiation were subcutaneous 
implanted the scaffolds -  3D-BM niche constructs providing from group 2 and 3 of the in 
vitro cell culture experiments. The only difference between both groups was that in 
Group 2 the scaffolds was xenotransplanted after 4 weeks in vitro culture, and in Group 3 
it was transplanted after 5 weeks.  
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Figure 7. Scheme of in vitro and in vivo experimental design 
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8.2 Analysis of human hematopoietic engraftment by flow cytometry 
 
Peripheral blood (PB) was aspirated from retroorbital sinus and bone marrow (BM) from 
the right femur were obtained 3 and 6 weeks after transplant the CD34+ cells, to analyze 
the presence of human cells by flow cytometry. All samples obtained were prepared as 
single cell suspensions in PBS, subjected to lysis of erythrocytes with ammonium chloride, 
followed by a 5 minutes wash at 700g and then resuspended aG1in in PBS.  
Human hematopoietic cells were distinguished from mouse cells by the expression of 
human CD45 antigen. For this purpose, samples were stained with FITC-conjugated anti–
human CD45 (Miltenyi Biotec, Bergisch Gladbach, Germany). For detection of  human myeloid 
and B-lymphoid cells samples were stained with PE-conjugated CD13 and APC-
conjugated CD19 (all from Becton Dickinson Biosciences, San Jose, CA, USA), respectively. 
Both subpopulations were analyzed only within the human CD45+ cell population. In all 
cases dead cells were excluded from the analysis, 10 min before acquisition, by  ¡7-
Amino-actinomycin D (7-AAD) (Becton Dickinson Biosciences, San Jose, CA, USA) staining.  
 
8.3 Histological and Immunofluorescence analysis 
 
Animals were sacrificed 6 weeks after the transplant by cervical dislocation after 
anesthetized with ketamina/xylazin. The femurs and 3D – BM niche implanted 
subcutaneously were dissected and fixed in 4% of paraformaldehyde at room temperature 
overnight. Samples were descalcified 24 hours for the femurs and 2 hours for the 
scaffolds, and then were embedded in paraffin. For the analysis, 5 µm thick sections were 
obtained in a Leica CM 2000 cryostat (Leica Microsystems, Nussloch, Germany) and placed 
onto glass slides. 
For histological assays was performed hematoxylin and eosin staining to evaluate 
morphological changes. 
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8.3.1 Detection of human cells in NOD/SCID mice 
 
Paraffin sections were de-paraffinized with xylene and then rehydrated in ethanol and 
water. For antigen retrieval, sections were subjected to 100ºC for 20 minutes in 10mM 
sodium citrate buffer (pH6), and then the nonspecific biding were blocked by 5% of normal 
donkey serum, bovine serum albumin and 0,2% of triton X-100 diluted in PBS for 60 
minutes in constant agitation at room temperature. 
The slides were incubated with a primary mouse monoclonal anti – GFP antibody (AbCam, 
Cambridge, UK) allowing the amplification of endogenous CFP signals of MSC, and also 
incubated with primary rabbit polyclonal anti- human mitochondria (AbCam, Cambridge, UK) 
to detect if expressing cells were from human origin. Primary antibodies were diluted in 
PBS following manufacturer's recommendations, and slides were incubated overnight at 
4ºC. 
Alexa Fluor448-conjugated anti- rabbit IgG and Alexa555 anti-mouse IgG were used as 
secondary antibodies (both from Invitrogen, Paisley, UK). After the final washes, 1 µg/ml 4’, 
6-Diamidine-2’ -phenyl indole, dihydrochloride (DAPI) in PBS was added and the cells 
were incubated at room temperature for 5 min. Slides were viewed with a Leica 
DMI6000B fluorescence microscope (Leica Microsystems GmbH, Germany) equipped with 
camera system. 
Protocol for immunohistochemical assay it is similar to the Immunofluorescence, but 
because the endogenous peroxidase activity is found in many tissues and can be 
detected by reaction with DAB substrate. The solution for eliminating endogenous 
peroxidase activity is by the pretreatment of the tissue section with hydrogen peroxidase 
prior to incubation of primary antibody. 
 It is used ABC - Avidin-Biotin Complex method (standard) for immunohistochemical 
staining. The peroxidase is then developed by the DAB because avidin is labeled with 
peroxidase, that produce different colorimetric end product.  
 
9. Statistical analysis 
 
For all statistical analysis, the SPSS 15.0 software (Chicago, IL, USA) was used. Median 
values and ranges were calculated for each variable. To explore the significance in the 
differences found between the different groups, the nonparametric Mann-Whitney U-test 
was employed. Differences were considered to be statistically significant when p < 0.05. 
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1. BM-MSC isolation and expansion 
 
Since MSC are recognized as adherent cells that are capable of extensive proliferation 
with a fibroblastic morphology and have the ability to differentiate into mesenchymal 
lineages, it was possible isolate this population according to their characteristics, figure 8. 
They were maintained until third passage and further characterized according to ISCT 
definition criteria. 
  
 
 
 
 
 
Figure 8. Sequential images of expanded hMSC culture. A – Initial culture morphology (40X); B – a single 
– shaped fibroblastic morphology (100X); C – evolution of the adherent cells until achieving confluence (40X).  
 
2. Analysis of immunophenotype and differentiation capacity 
 
Cell surface antigen expression of MSC in third passage was analyzed by flow cytometry. 
This cells did not express hematopoietic lineages markers such as CD14, CD19, CD34, 
CD45 and neither HLA-DR. They were positive for CD73, CD90, CD105, CD166 and 
CD44 thereby demonstrating an characteristic MSC immunophenotypic profile, Figure 9. 
 
 
Figure 9. Flow cytometry characterization of hMSC – representative diagrams were obtained from 
confluence cultures of hMSC at passage 3, in the left represents the positive markers and in the right 
represents the negative markers. Blue stain represents unlabeled control cells (absence of antibodies).  
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The tri-lineage differentiation ability of MSC cultures was tested at passage 3 upon culture 
in osteogenic, adipogenic, and chondrogenic medium. In vitro differentiation was 
demonstrated in all cases, after specific assessment of alkaline phosphatase activity, oil-
red-O, and type II collagen staining, respectively, figure 10.   
 
 
Figure 10. Differentiation potential after exposure MSC to differentiation medium. Osteogenic 
differentiation was confirmed by (A,B) cytochemical staining for alkaline phosphatase. (C,D) 
immunocytochemical staining for collagen type I demonstrating chondrocyte differentiation. (E,F) Lipid-filled 
adipocytes detection by oil red O staining. Control MSC maintained in expansion medium (A,C,E) and in 
differentiation medium (B,D,F). Data are representative of three independent experiments.    
 
3. Efficiency transfection of MSC with lentiviral vectors containing CFP protein 
 
The MSC used in this study had high efficiency presented in all cases expression of CFP 
higher than 90% when analyzed by flow cytometry, figure 11.  
 
 
Figure 11: Representative case of MSC - CFP
+
 cells observed by flow cytometry 
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4. HSC characteristic 
 
The average volume of the UCB used was 337ml (range 289-675 ml, including 
anticoagulant). The median recovery of MNCs was 137,5x106cells/unit (range 122-
168x106cells). In the figure 12 illustrate the percentage of purified CD34+ cells that were 
used for in vitro and in vivo assays, isolated through immunomagnetic beads was higher 
than 90% when analyzed by flow cytometry. 
  
 
 
 
 
 
 
Figure 12. Percentage of CD34
+
 cells in a representative case. Cells were isolated by immunomagnetic 
beads and purity analyzed by flow cytometry. 
 
5. In vitro cell cultures experiments  
 
To mimic bone marrow stroma 2x105 MSC/ml were seeded on Conduit TCP. This 
concentration was selected based on optimal cell attachment frequency (data not 
provided), growth rate and growth cavity43. After 7 days of stromal induction with LTBMC, 
2x105 CD34+ cells were seeded onto stromal cell-Conduit TCP constructs. Identical 
cultures were also performed on 2D plates (without the scaffolds of Conduit-TCP) to 
establish if 3D biomimetic niche can support the maintenance and proliferation of HSC, 
Figure 13.  
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Figure 13. MSC culture in the biomimetic 3D-BM niche. After 7 days of induction, morphological analyses 
on the stroma of different experiments were performed using an inverted microscopy. A - Stromal layer 
confluence on 2D plates – control (100X), sequential images (B,C and D – 10X, 20X and 40X) were the cells 
grew along and inside the scaffold cavity. 
Scaffold in brightfield (E) and in fluorescence (F)  MSC-CFP
+
 inside the scaffolds, 40 X  
 
5.1 Long-term bone marrow culture (LTBMC) 
 
To confirm the maintenance of hematopoiesis in vitro under different experimental 
conditions, layer confluence, presence of cobblestone areas, adipocytes and clonogenic 
cell assay from LTBMC were evaluated weekly during the 5 weeks.  
 
5.1.1 Stromal layer confluence  
 
During the culture time the stromal layer confluence in the control group (G1) always 
reached a high percentage of confluence (95-100%). On the other groups the stromal 
layer behavior was different. In group 2 (G2) – 2D+3D system, the confluence was lower 
when compared with the control group with a decrease of 20% from the fourth week. MSC 
attached into the scaffolds were observed during the five weeks of culture, figure 14. 
The third in vitro group (group G3 – 3D system) was not scored for stromal layer 
confluence or the presence of cobblestone areas and adipocytes because the objective of 
this group was to just had the stroma inside the scaffold (3D niche), and therefore those 
standard LTC parameters cannot be quantified in this setting with an inverted microscope.  
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Figure 14. Adherent stromal layer confluence evaluation during the five weeks. Data represents the 
median. G1=control (MSCs without the scaffold); G2=2D/3D system (adherent stromal layer/Conduit TCD). 
 
5.1.2 Presence of cobblestone areas and adipocytes 
 
Adipocytes appeared from the first week in both groups (G1 and G2) and remained until 
the end of the in vitro experiments, figure 15. In G1 (control) the percentage of adipocytes 
was always superior when compared with G2 (with scaffold), with an increase in week 2 
and maintained until week 5. Nevertheless, in G2 the number of adipocytes decreased 
from the third week, which was related to the decrease of the stromal layer. To score 
adipocytes an inverted phase – contrast microscopy (20X) was used and assigned with 0 
– absence of adipocytes, 1 – one adipocyte in 10 fields, 2 – one adipocyte in 2 fields and 
3 – two adipocytes in 1 field (number of adipocytes per field). 
 
 
Figure 15. Score of adipocytes cells observed in LTBMC, during the five weeks, with respect to 
different culture conditions. Data represents the median. G1=control (MSCs without the scaffold); 
G2=2D/3D system (adherent stromal layer/Conduit TCP). 
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Cobblestone areas – forming (CAFC) assay was performed to assess the proliferative 
capacity of CD34+ cells when cultured on different experimental conditions, figure 16.  
At different time – points appeared small colonies of round cells that grew underneath the 
stromal layer. 
The cobblestone areas were scored using the same criteria used to score adipocytes. In 
control group (G1) CAFC appeared in the second week. In some cases it was impossible 
to count because the hematopoietic cells covered the entire microscopic field. In G2, 
CAFS appeared one week latter and in a lower percentage when compared to G1. A 
decrease of CAFS was observed in the fifth week was which was consistent with the 
results previously described.  
 
Figure 16. CAFC observed in a LTBMC during the five weeks, in the different culture conditions. Data 
represents the median. G1=control (MSCs without the scaffold); G2=2D/3D system (adherent stromal 
layer/Conduit TCP). 
 
 
 
 
 
 
 
 
 
 
Figure 17. Long term bone marrow culture 5 weeks after seeding CD34
+
 cells. Cobblestone area formed 
in 2D system and in 2D/3D system - adherent layer co-cultured with Conduit TCD (A, B) dark cells associated 
with a fat cells (C, D) together with phase-birth supernatant cells, 10X 
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5.1.3 Cell-culture in vitro assays  
 
5.1.3.1 Number of cells produced from long-term bone marrow culture (LTBMC) 
 
In order to ascertain how the different co-culture systems affect cell numbers produced 
from LTBMC, supernatants from the different experimental groups were weekly counted 
(Figure 18). As it is shown, total number of non - adherent cells from 2D/3D culture-
systems increased during the five weeks of LTBMC, and in last week was significantly 
higher (p<0,01) compared with other groups. 
 
 
Figure 18. Long – term bone marrow culture data. Cells recovered during the 5 weeks of culture. Data 
represents the median (range). G1=control (MSC without the scaffold); G2=2D/3D system (adherent stromal 
layer/Conduit TCD); G3=3D system (just Conduit TCP).  
 
5.1.3.2 Measurement of CFU-GM from LTBMC experiments 
 
Colonies of CFU-GM in standard methylcellulose assays were performed from cells 
released to the supernatant during the five weeks of LTBMC in each experimental group. 
Results are shown in table 5.  Data suggest that all groups have similar CFU-GM content 
during the five weeks. Number of colonies decreased in the second and increased in 
fourth week, and dropped in the fifth week.   
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 Week 1 Week 2 Week 3 Week 4 Week 5 
G1 
(control) 
32,3 
(15,5-78) 
6,0 
(0,2-27) 
5,6 
(0,4-40) 
190 
(100-310) 
1,8 
(0-27) 
G2 
(2D + 3D system) 
29,8 
(0,08-58) 
13,2 
(0,2-34) 
16,3 
(0,07-30) 
165 
(100-300) 
3,7 
(0-26) 
G3 
(3D system) 
42,2 
(18-72) 
5,1 
(0,2-14) 
13 
(0-39) 
100 
(100-310) 
3,2 
(0-20) 
 
Table 5. CFU-GM/10
3
 weekly produced from supernatant cells of different assays.    
 
 
G1=control (MSC without the scaffold); G2=2D/3D system (adherent stromal layer at 2D conventional system 
with Conduit TCD to create a 3D niche); G3= 3D system (just Conduit TCP with the stroma inside the 
scaffold). Data represents the median (range). 
 
6 In vivo experiments 
 
To verify if human bone marrow (3D niche) from the in vitro cultures have homing capacity 
in vivo, xenotransplantation experiments were performed in sublethally irradiated 
NOD/SCID mice 
 
6.1 Human hematopoietic cell engraftment in xenotransplanted NOD/SCID mice 
 
Percentage of human CD45+ cells in PB was higher in group 2 (11.6%), that included 
animals that received a subcutaneous implant of 3D BM niche after 4 weeks in culture, 
compared to group 1- in vivo construction of 3D BM niche (8.9%) and Group C – animals 
with a subcutaneous implant of in vitro-developed3D BM niche after 5 weeks in culture 
(6.19%), table 6.   
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Table 6. Percentage of human hematopoietic cells (hCD45) in peripheral blood (PB) at 3 weeks 
after xenotransplanted. 
 
 
 
 
 
 
 
 
Data represents the median (range) 
*Higher% of hCD45 cells (p<0,05) when compared with group 1 (G1) -  in vivo 3D niche construct; †Lower % 
of hCD45 (p<0,05) when compared with group 2 (G2) – xenotransplant the in vitro 3D niche construct 
(MSC/CD34
+
/scaffold) past 4 weeks in culture. Group 3 (G3) the same that G2 but with the construct in culture 
for 5 weeks.  
 
At 6 weeks after the xenotransplant PB and BM were analyzed. Engraftment levels were 
slightly higher in PB from group 1. By contrast in BM engraftment was significantly higher 
in G2, table 7. 
Additionally, in BM and PB human cells committed to both lymphoid (positive for CD19) 
and myeloid lineages (positive for CD13) were detected. Myeloid cells were the 
predominant population within the human population in both in vitro 3D niches constructs 
groups (2 and 3), with a higher percentage for group 2. In Group 1 (in vivo) B-cells were 
the predominant human cell population in both compartments (BM and PB) with significant 
differences when compared to group 2, table 8 
 
 
 
 
 
 
 
 
 
 
 
 
 
%hCD45 
PB 
G1 
n=5 
8,9 
(7,07-10,58) 
G2 
n=5 
11,76* 
(8,63-16,74) 
G3 
n=6 
6,19† 
(5,01-10,54) 
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Table 7. Percentage of human hematopoietic cells in BM and PB in NOD/SCID mice determined 6 
weeks after transplantation.    
 
 
 
 
 
 
 
 
 
 
Data represents the median (range) 
Peripheral Blood (PB): 
*Higher percentage of human CD45 cells (p<0,05) when compared with G2 
Blood Marrow (BM): 
*Significant differences of human CD45 cells percentage (p<0,05) when compared with G1; 
†
Low percentage of human CD45 cells (p<0,01) when compared with G3  
G1 (group 1) - in vivo 3D niche construct; G2 (group 2) – xenotransplant the in vitro 3D niche construct 
(MSC/CD34
+
/scaffold) past 4 weeks in culture. G3 (Group 3) the same that GB but with the construct in 
culture for 5 weeks 
   
Table 8. Percentage of human lineage-positive cells expressing hCD19 and hCD13 in BM and PB 
of NOD/SCID mice 6 weeks after transplantation.    
 
 
 
 
 
 
 
 
 
Data represents the median (range) 
Peripheral Blood (PB): 
*Higher percentage of human CD13 cells (p<0,05) when compared with G3; 
Blood Marrow (BM): 
*Significant differences of percentage of human CD19 cells (p<0,05) when compared with G3; 
G1 (group 1) - in vivo 3D niche construct; G2 (group 2) – xenotransplant the in vitro 3D niche construct 
(MSC/CD34
+
/scaffold) after 4 weeks in culture. G3 (Group 3) the same that G2 but with the construct in 
culture for 5 weeks. 
 
 
 
%hCD45 
PB 
 
BM 
G1 
n=5 
7,35* 
(6-13) 
5,45 
(2-11) 
G2 
n=4 
3,74 
(2-6) 
11,76* 
(9-17) 
G3 
n=6 
6,33 
(6-8) 
5,63†† 
(1-7) 
 
 
                 PB 
%hCD19         %hCD13 
               BM 
%hCD19       %hCD13 
G1 
n=5 
 4,39                   1,28 
(0-32)                 (1-3) 
16,98*                2,23 
(0-88)              (0-18) 
G2 
n=4 
 1,11                   4,47* 
(0-11)                 (2-6) 
    0                    9,52 
   ---                 (3-26)   
G3 
n=6 
 0,82                   1 03          
(0-3)                    (0-4)  
  0                    7,35 
   ---                 (2-42) 
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In order to know whether IV CD34+ cells could migrate to the 3D-BM niche constructs and 
produce hematopoietic chimerism, on group 1, in vivo 3D niche construct, human 
hematopoietic cells (CD34+) were transplanted intravenously (IV) in 4 mice and 
subcutaneously (SC) within in 2 mice. Despite no significant differences detected lower 
percentage of human CD19+ cells were observed in cases with CD34+ subcutaneously 
injected (table 9)  
 
Table 9. Percentage of human hematopoietic cells and there lineage on group 1, BM and PB, in 
NOD/SCID mice determined 6 weeks after transplanted. 
 
Group 1 
                                              BM                                                       PB    
                            %hCD45      %hCD13          %hCD19         %hCD45         %hCD13          %hCD19 
IV 
n=4 
9,40 17,62 25,71 9,26 0,63 5,54 
SC 
n=2 
3,49 0,89 1,12 6,48 2,38 ND 
Data represents the median (range) 
IV – intravenously, SC – subcutaneously, BM – bone marrow and PB – Peripheral Blood. 
 
7. Ex vivo studies 
 
From the total of the 18 mice used, two were eliminated from the experimental study 
because premature death of animals with no possibility to perform histologic assessment 
in these two cases, corresponding to a yield of 89% induction. 
Yield = number of animals at the end / number of animals at the beginning = 16/18 
= 0.89 
Median Animal weights were: Group A = 18,90 (17-22), Group B= 19,90 (19.23) and 
Group C= 20,35 (18-22) without significant differences between experimental groups.   
.   
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7.1 Macroscopic examination 
 
Macroscopic and microscopic assessment of the subcutaneous implants and femurs was 
performed. Macroscopic observations o the skin showed in all groups high vascularization 
especially in Conduit TCP areas. 
 
 
Figure 19. Representative macroscopic image of murine skin. Arrows mark the areas where were 
implants were located. Right image illustrate a scaffold of approximately 3 mm of diameter. 
 
7.2 Histological analysis  
 
In all groups the 3D-BM niche construct appeared in the histological analysis integrated 
within the surrounding tissue and without an evident foreign body reaction (no obvious 
inflammation). 
Blood vessels were found inside implanted scaffolds especially in groups with scaffolds 
derived obtained after “in vitro culture” (Groups 2 and 3). Non-physiological spaces 
originated from the scaffolds were also found, which were surrounded by a layer of cells 
adhered to the biomaterial and hematopoietic cells.     
In the implanted 3D-BM niche construct from in vivo group 1, the tissue formation showed 
morphology similar to murine tissue with a higher quantity of adipocytes (fat), figure 20. In 
all three groups had within the tissue scaffolds some cells with fusiform morphology 
(mesenchymal), predominantly in the in vivo groups 2 and 3, figure 21 and 23 
respectively.  
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Figure 20. Analysis of in vivo 3D-BM niche constructs into the subcutaneous tissue of 
immunocompromised mice (group 1). The scaffolds with MSC were subcutaneous implanted on NOD/SCID 
mice and induced to form stroma for 7 weeks, in vivo. Then, intravenously and subcutaneously with CD34
+
 
cells from UCB were transplanted. Six weeks later mice were sacrificed and ex vivo studies were performed 
on the implants.. Scaffolds integrated well with surrounding tissues constituted mainly by fibroblastic cells 
figure B (100X). The morphology of tissue constructs were similar to murine tissue. A high number of 
adipocytes and small and large blood vessels were observed(*), figure A (10X). 
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Figure 21. Histology representative of group 2 - in vitro 3D-BM niche constructs 6 weeks after being 
subcutaneously implanted in NOD/SCID mice. The 3D-BM niche obtained from cultures 4 weeks cultures 
were maintained for 6 weeks on the mice. The scaffolds were decalcified for 2 hours, then paraffin-embedded, 
and finally stained with hematoxylin/eosin. In figure A (10X) the scaffolds are sourrounded by polyclonal cells 
(maybe MSC) and also rounded cells suggestive of hematopoietic cells. figure B (100X). The morphology of 
tissue constructs is different from the murine tissue. Many small and large blood vessels can be detected (*) 
 
 
Figure 22. Histology representative of group 2 - in vitro 3D-BM niche constructs 6 weeks after 
subcutaneous implant in NOD/SCID mice. With a magnification x 100 a total integration of the scaffold 
within the surrounding tissue, where sometimes formed a capsule of fibroblastic cells. 
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Figure 23. Histological stain representative of group 3 - in vitro 3D-BM niche constructs 6 weeks after 
subcutaneous implantation in NOD/SCID mice. The 3D-BM niche constituted by MSC and HSC (CD34
+
) 
from in vitro long term cultures of 5 weeks were implanted in immunocompromised mice and maintained for 6 
weeks. Can be observed that the implants integrated in the tissue with the presence mostly of polygonal 
morphology cells, many blood vessels and new tissue formation   
 
 
7.3 Localization and spatial distribution of human cells (hematopoietic and MSC)   on 3D-
BM niche constructs and in the murine BM compartment  
 
In order to verify tissue scaffold formation from human cells, slides were stained with an 
anti-human mitochondria antibody. Because the constructs were formed with MSC - CFP 
a monoclonal anti – CFP antibody was used to confirm in situ the presence of human 
MSC.  
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7.3.1 immunohistochemistry analysis of 3D- BM niche constructs  
 
Human cell were detected by their positivity to anti-human mitochondria antibody showing 
an intense brown reactivity spots on the cytoplasm. Spindle-shaped cells surrounding the 
scaffolds were manly human cells. Human positive cells were also found in the basement 
membrane surrounding blood vessels formatted in the scaffolds, figure 24.  
 
Figure 24. Subcutaneous 3D-BM niche constructs staining with anti-human mitochondria antibody. 
Immunohistochemical analysis of 3 µm paraffin cross-section through Conduit TCP containing mitochondria 
positive cells (human) stained with DAB showed positive brown spots on the cytoplasm. (A) (D) positive cells 
with polygonal morphology in contact with the scaffold (40X) and with (B) other morphology (40X). (C) human 
cells associated within vascular structures (100X). 
S – scaffold; BV – blood vessels; (A), (B) – in vitro Group 1; (C) – in vitro Group 2; (D) – in vitro Group 3; (A, B 
and C) were contrasted with hematoxylin.   
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7.3.2 3D-BM niche constructs immunofluorescence analysis 
 
In other to confirm immunohistochemical results and to detect simultaneously human 
mesenchymal stem cells and hematopoietic cells immunofluorescence studies were 
carried out. Cells with polygonal morphology expressed CFP proteins (green) and were 
mitochondria positive (red) confirming the presence of human MSC on the scaffolds after 
13 weeks of subcutaneous implants on group 1 and 6 weeks on group 2 and 3. The MSC 
contributed to tissue scaffold formation (figure 25, B and E) as well as blood vessels, 
figure 25 - H and I.   
 
Figure 25. Subcutaneous 3D-BM niche constructs analysis with anti-human mitochondria and anti – 
CFP antibody.  Immunofluorescence  representative analysis of 3 µm paraffin cross-section through Conduit 
TCP containing MSC- CFP
+
 cells (green) (B)(E) showing engraftment in Conduit TCP of human MSC (green 
and red)(C) (F) . Positive mitochondria (red) (*)CFP negative cells were identified suggesting the presence of 
possible human hematopoietic cells. DAPI (blue) was used as nuclear counterstaining in all panels. 
Magnification x 100.  Arrows indicate human MSC. BV – Blood vessels; (A) (D) DAPI and Mitochondria; (B)(E) 
DAPI and CFP
+
 cells; (C)(F)(G)(H)(I) overlay DAPI (blue), Mitochondria (red) and CFP
+
 (green) cells. 
(A)(B)(C)(H)(I) – in vitro group 2; (D)(E)(F) – in vitro group 3; (G) – in vitro group  
  Results 
 
49 
 
7.3.3 Immunohistochemical and immunofluorescence analysis of murine femurs.   
 
Immunohistochemical assays analysis showed that human hematopoietic cells were 
present within mouse bone marrow, with the highest proportion observed in the G2 mice. 
Also anti-mitochondria antibody positive cells with fibroblastic morphology (human MSC) 
were observed in the endosteal zone (Figure 26 C) and in close relationship with human 
hematopoietic cells (Figure 26 D). 
When immunofluorescence analysis was formed data confirmed immunohistochemical 
findings, showing hematopoietic cells distributed within mouse BM (Figure 25 E and F). 
Also with the immunofluorescence approach showed human MSC in endosteal zone 
(Figure 27 and 28). 
For both assays (immunohistochemical. and immunofluorescence.) were realized 
negative controls for protocol validation (Data not provided).  
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Figure 26. In situ visualization and spatial organization of human hematopoietic and MSC in the BM 
compartment of NOD/SCID mice at 6 weeks after xenotransplatation. Representative bone/bone marrow 
of 3 µm paraffin cross section were immunohistochemically stained using anti-human mitochondria (dark 
brown spots) and immunofluorescence stained using anti-mitochondria (red) and anti-CFP antibodies (green). 
(A) large quantities of mitochondria positive cells were possible to identify on trabecular bone of group 2 when 
compared with group 1 (B). Osteoblast positive cells were found in bone tissue (C) mitochondria positive cells 
(*)  in closely proximity to bone  (D) the results confirmed human cells (red) on murine trabecular bone (E)(F). 
DAPI (blue) was used as nuclear counterstain in all panels. (A) (D) counterstained with hematoxylin; (E)(F) 
overlay DAPI (blue), anti- human mitochondria (red) positive cells. (A)(B) Magnification x 40 and (C)(D)(E)(F) 
x100.   
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Figure 27. In situ visualization of human MSC in the murine bone from the in vivo group 2 –3D-BM 
niche constructs with.  (A) positive cells for human mitochondria were detected (red) that were also CFP
+ 
cells, representing human MSC. (B) DAPI (blue) was used as nuclear counterstain. Magnification x 40.     
 
 
Figure 28. Site-specific differentiation of human eCFP-MSC in the murine BM compartment. The eCFP-
MSC was determined by immunofluorescente staining for lineage-specific antigens. The MSC-CFP
+
 (green) 
were located in endosteal zone (A) and positive human cells (red) anti-human mitochondria antibody (B). 
DAPI (blue) was used as nuclear counterstain. Magnification x 100.  
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After the description of the hematopoietic stem cell “niche” that regulates the “stemness” 
of HSC, its study has deserved an increasing scientific interest.  
HSC are not independent units, they need to reside in a dynamic microenvironment where 
cell-to-cell interactions, soluble factors, and three-dimensional spaces provide the 
ultrastructure for their survival. The cellular constituents forming the HSC niche in the BM 
are still unclear, wherever different studies show that osteolineage cells controls the niche 
size17. 
On the other hand, after the first successful transplantation in 198976, umbilical cord blood 
has been used as an established source for HSCT, although its use is clinically limited by 
the low number of progenitor cells. Ex vivo expansion has become an alternative to 
increase the cell dose available for transplants77.  
The most promising model of HSC expansion involves the use of a three-dimensional 
(3D) culture system43 that provides a better alternative to the classic static cultures where  
high doses of cytokines have to be added to allow the proliferation and differentiation of 
many of the progenitor and precursor pool on UCB78.  
Hypothetically the 3D culture systems try to reproduce the in vivo hematopoietic 
microenvironment, but at least three components41 are necessary: 
- soluble factors (cytokynes); 
- supportive cells and adhesion molecules; 
- three – dimensional geometry. 
It has been demonstrated that MSC in culture promote the expansion and differentiation of 
HSC by secreting cytokines25 including a set of well-established interleukins, leukemia 
inhibitory factor (LIF), Flt-3 ligand, SCF, G-CSF and GM-CSF, and express surface 
molecules, including intercellular adhesion molecule and vascular cell adhesion molecule 
to behave as  “feeder layers”  implicated in the regulation of hematopoiesis. 
Systemic studies of co-transplantation of HSC with MSC in the context of HSCT25 have 
shown to increase chimerism or/and accelerate hematopoietic recovery in animal models 
and in humans59.      
One of our first objectives was to develop an in vitro 3D-model with human stroma cells 
induced from human MSC and a biocompatible scaffold – ConduitTM – TCP, able to 
support the maintenance and expansion of CD34+ cells providing from UCB. Some 
reports indicate that co-cultures with MSC can efficiently support79 the expansion and 
differentiation of HSC without the need of adding exogenous cytokines44 since they can  
provide an effective microenvironment (with both soluble and non soluble signals). 
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Previous results from our group80 suggests that the ConduitTM – TCP can provide a 3D 
system similar to human bone able to support the expansion and differentiation of human 
MSC when compared to other biomaterials, and at the same time differentiate into 
osteogenic linage creating an incipient bone matrix. 
Other studies demonstrated the capacity of maintaining and expanding HSC in vitro using 
a scaffold with human mesenchymal stem cells, however few studies demonstrate the in 
vivo functionality of these constructs42. For this reason we have developed an 
experimental model based on a biomimetic niche formed by a biocompatible and 
osteoconductive biomaterial - ConduitTM – TCP- and human MSC differentiated into 
mature stromal cells (3D system) that could maintain and expand HSC in long term 
cultures. This 3D system was compared with the conventional two dimensional culture 
system.  
The data provided from long – term marrow cultures (LTMBC) confirmed the maintenance 
of hematopoietic cells in vitro under different experimental conditions (2D, 2D+3D and 
only 3D system), where the stromal layer confluence, the presence of cobblestone areas 
and adipocytes were detected during the five weeks of culture. The formation of an 
osteogenic niche inside the scaffolds was demonstrated by detecting MSC-CFP+. 
On the group presented with the two systems (stromal layer cultured with Conduit-TCP), 
cobblestone areas appeared one week later than in group control (only 2D system), this 
can be explained by the capacity of HSC to migrate to specific niches and to be retained 
into the scaffold by their adhesion to the stroma45. For this reason cobblestone area 
results for this group could be underscored because the active areas of hematopoiesis 
inside of scaffolds could not be detected.  
It has been demonstrated that co-transplantation of MSC with CD34+ cells from human 
UCB results in the acceleration of the engraftment81. These results are related to the role 
of MSC in control of the hematopoietic niche. However, animal models could be more 
reliable in order to analyzed LT-HSC behavior.  
Primitive human hematopoietic cells can be assayed on the basis of their ability to 
repopulate immune-deficient NOD/SCID mice, using a xenotransplantation model that 
provides a powerful tool to characterize long-term engraftment and multi-lineage 
differentiation of human HSC82. 
To assess the LT-HSC and verify the functionality of the in vitro 3D-BM niche construct in 
vivo, different experimental niches were implanted subcutaneously in irradiated 
NOD/SCID mice. The constructs were prior developed from in vitro cultures during 4 and 
5 weeks (groups 2 and 3), respectively. Both groups were compared to the control group 
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(group 1) in which the niche was directly developed in vivo by the subcutaneous delivery 
of the scaffold and MSC.  
At third week after xenotransplantation human hematopoietic cells (CD45+) were detected 
both in PB in all experimental groups, with higher human chimerism in the group where 
the scaffolds from 4-weeks of in vitro cultures were implanted. These data are in 
agreement with the in vitro experimental results where a decrease of CFU-GM formation 
and cobblestone area in cultures with five weeks was observed, suggesting that an higher 
number of LT-HSC were presented inside 3D constructs that stay in culture for 4 weeks 
and then during the 5th week they began to differentiate. 
The percentage of human hematopoietic cells at the two time points of analysis (3rd and 
6th week) was similar on in vivo group 1 (control) and group 3 where the scaffolds 
providing from in vitro cultures with five weeks, but with differences in the percentages of 
myeloid and lymphoid cells. In this regard, in group 1 both cell types were detected 
whereas in group 3 the CD13+ (myeloid) subset accounted of most of the human cells 
observed.  
When results of human chimerism were analyzed at 6 weeks after transplant we observed 
that, in BM the highest proportion of human hematopoietic cells was detected in G2 but by 
contrast this group showed the lower expression in PB. This feature is difficult to interpret 
but perhaps a higher proportion of immature progenitors can migrate from the construct to 
BM and longer follow up could result in higher proportion of human cells in PB.  
Ours data suggest that ex vivo expansion of CD34+ (UCB) using in vitro 3D-BM niche 
construct leads to myeloid differentiation, but with a closer look to the group where the 
niche was constructed in vivo, the percentage of human lymphoid cells detectable on the 
mice transplanted with CD34+ cells subcutaneously was lower compared with those who 
were transplanted intravenously. It can be hypothesized that this effect is not the result of 
the ex vivo expansion of HSC but can be related with the scaffold used on the assays 
which leads to the predominant myeloid differentiation. There is not any prior study in the 
literature exploring the ability of ConduitTM TCP as 3D scaffold to support in vitro or in vivo 
the hematopoiesis. Most of the studies have focused on assessing its osteogenic 
potential74 combined with human MSC in vivo, showing new ectopic bone formation after 
4 weeks of implantation, with the differentiation of MSC into osteoblasts in vivo83. This 
biomaterial provides a skeletal support for the growth of osteogenic cells creating enough 
space for new bone formation. 
Analyses of human hematopoietic cells by flow cytometry in our system provides 
information on the engraftment kinetics for CD45+ cells and cell subsets, but does not 
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allow the assessment of the spatial distribution of these cells. For this reason, 6 weeks 
after transplantation mice were sacrificed and the implants as well as the BM from femurs 
ex vivo evaluated.  
Firstly, as it would be expected, ConduitTM-TCP was not rejected after subcutaneous 
implantation, since no inflammatory response was observed from a morphological and 
histological point of view. As mentioned, this is not surprising, specially in an 
immunocompromised host. Blood vessels, immature connective tissue and adherent cells 
with polygonal morphologies were found within the implants. However there were several 
differences among the groups. For instance, the presence of adipocytes and connective 
tissue was characteristic in the group in which niche was formed in vivo, whereas on in 
vitro constructs more blood vessels, capillaries and hematopoietic cells were detected, 
and the fusiform cells  formed an encapsulating cell layer surrounding the scaffold. 
The finding of more adipocytes in the control group, where the MSC were induced for 7 
weeks in the ectopic implant may be related to differences in the methodology that 
included a different time of contact between MSC and CD34+ cells. It has been shown that 
microenvironment behavior is influenced by its contact with hematopoietic cells.  
The identification of the phenotype was possible because the human MSC that are 
responsible for the formation of 3D-BM niche were genetically marked.  The engraftment 
and differentiation of MSC-CFP+ cells were determined by immunofluorescence staining. 
These cells were located on the blood vessels basement that seemed to be involved in 
the formation of new tissue. In all groups positive MSC-CFP+ were detected in 3D-BM 
niche constructs but it was not possible to identify if these elongated cells were in contact 
with the scaffolds because the scaffold material could not be seen. This problem was 
minimized with immunohistochemical stains that allowed locating the positive human cells 
stained with anti-mitochondria antibody. Our findings showed the human origin of these 
cells in the tissue.  
Human mitochondria positive cells and at the same time negative to CFP were identified 
as possible human hematopoietic cells. 
The routes of human MSC administration have been investigated in previous studies on 
murine models, where they can be an important factor in the reconstitution of functional 
human hematopoietic microenvironment. The visualization of human MSC in murine BM 
compartment it was not observed when these cells were intravenously administered, since 
most of them are trapped in the microvasculature of the lungs preventing their homing to 
BM. When these cells are intra-bone transplanted neither can be detected in the 
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contralateral bone to the one that received the transplant, suggesting minimal migrations, 
as opposed to human HSC.  
Our data show that in vitro group 2, bone marrow showed the presence of human MSC-
CFP+ cells coming from the 3D-BM niche construct that had been subcutaneously 
implanted and contradict previous findings about the capability of migration of MSC. 
Furthermore this population of cells was preferentially located on the surface of the bone 
(endosteal region) and in close relationship with human hematopoietic cells. It could be 
suggested that this hematopoietic cells could have attracted MSC to the murine BM and 
bone. Immunohistochemical analyses lead us to identify positive human cells with the 
morphology spindle-shaped of osteocytes extending into the canaliculi bone. 
Previous reports have demonstrated the therapeutic potential of bone marrow 
transplantation in children with severe osteogenesis imperfect84, suggesting that 
mesenchymal cells can engraft and function in skeletal sites and differentiate into 
functional osteoblasts85. 
The fact that in the only group where human MSC were detected in BM was the group 
where 3D-BM niche constructs were implanted after 4 weeks in culture (in vivo group 2), 
may be related to the results of in vitro experiments where the in vitro hematopoetic 
activity was higher in the LTBMC established for 4 weeks.  
It will be interesting to assess in the future the differences in gene expression depending 
on the condition of culture (2D versus 3D system) 86.  
Since MSC have been demonstrated to contribute for tissue repair, it will be also 
interesting to study if in this in vitro experimental model MSC can provide a “trophic 
activity”87  capable of producing a variety of factors, as cytokines and peptides that 
influence on biological functions, including angiogenesis. Stromal derived factor 1(SDF1)88 
is expressed by osteoblasts, endothelial cells and BM stroma cells has been involved in 
the regulation of primitive HSC both in vivo an in vitro89. This cytokine plays an important 
role in cell trafficking and homing of CD34+ stem cells, SDF1/CXCR4 (receptor for SDF1) 
are essential for MSC migration to the sites of injury. In vitro studies90 indicate that the 
addition of MSC to damaged stromas could improve SDF1 secretion and correlates with 
higher level of CXCR4 expression on CD34+ cells. 
Perhaps, the most shining results of the result of the present study is to show that 3D-BM 
niche constructs can expand HSC from UCB in vitro and these cells can engraft in the 
murine model. Even these cells “in vivo” can expand and migrate to murine BM. However 
it should be remind that the Conduit-TCP can be responsible of a decrease in the human 
lymphoid compartment.    
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HSC can differentiate following a hierarchical process that is often dictated by intrinsic 
actions of hematopoietic transcription factors91.  
The Notch signaling pathway89 is one of the most important regulate cell fate in a variety 
of cellular systems. Some transmembrane glycoprotein receptors such, Jagged 1, Jagged 
2 and Delta 1, 3 and 4 initiate the activation of Notch signaling92. Some reports show that 
Delta 1 and Jagged1, have differential effects in human lymphoid differentiation93.  
Future studies in Notch signals may be important to verify why the CD34+ cells from UCB 
loss or reduce their capacity to differentiate in lymphoid lineage in this culture system. 
These feature future studies can illustrate the inter-relationship between the niche and 
stem cells and could lead us to evidence the molecular events that regulate the transition 
from multipotency to unipotency, during lymphopoiesis. Progenitors undergo a stepwise 
lineage restriction process where they can express multiple lymphoid-affiliated genes, 
such as those enconde TdT, IL-7Rα and EBF, in addition to RAG194 could be over or 
down expressed.         
 
In summary, the 3D-BM niche constructs allowed the growth, differentiation and migration 
of HSC in a 3D humanized environment effectively mimicking the natural in vivo bone 
marrow environment that allows the maintenance and proliferation of hematopoietic cells 
both in vivo and in vitro. This model permits the study of normal and pathological 
hematopoiesis and its relationship with the stroma. 
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1. Constructs of Conduit TCP loaded with human BM stroma derived from MSC are able 
to support the in vitro maintainance and proliferation of CD34+ cells from UCB. 
 
2. The 3D-BM niche constructs obtained from 4-weeks cultures when implanted 
subcutaneously in NOD/SCID mice allow the in vivo homing, lodgment and 
engraftment of human hematopoietic cells. 
 
2.1. The human MSC from these 3D implants are responsible of new tissue formation 
(contributing also to angiogenesis) on the ectopic bone. From the implants they 
can migrate to the murine BM of the femur, preferentially homing in endosteal 
region and in close relationship with human hematopoietic cells. 
 
3. 3D-BM niche constructs can regulate HSC behavior depending on the administration 
route: when intravenously injected, UCB progenitors preferentially differentiate into 
human B-lymphoid cells whereas they form mainly myeloid cells when injected 
subcutaneously. 
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